TENAGA ALIH DAYA/OUTSOURCING Menyediakan Jasa Tenaga Alih Daya (TAD) profesional untuk meningkatkan performa bisnis Anda
In STEP 1 [1] , the largest trial with 1,961 participants [1] , patients receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021)
But this time, the change is coming from the consumers biology, not just preferences, prices or policy
Dosing is typically gradual and titrated upward to minimize side effects and allow the body to adjust comfortably
doi: 10.1038/nature08938 60 YangDRWangMYZhangCLWangY
For example, the SELECT trial revealed that patients on semaglutide maintained an average weight loss of -10.2% over four years (208 weeks), while the placebo group only saw a modest -1.5% reduction